References
- Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the
recognition of the SARS-CoV-2 by full-length human ACE2. Science.
2020.
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL,
Hui D, et al. Clinical characteristics of coronavirus disease 2019 in
China. N Engl J Med. 2020. PMID: 32109013.
- Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y,
Zhou Y, Prevalence of comorbidities in the novel Wuhan coronavirus
(COVID-19) infection: a systematic review and meta-analysis,
International Journal of Infectious Diseases
- Toshiyuki Matsumoto, Ryoji Ozono, Tetsuya Oshima, Hideo Matsuura,
Taijiro Sueda, Goro Kajiyama, Masayuki Kambe, Type 2 angiotensin II
receptor is downregulated in cardiomyocytes of patients with heart
failure, Cardiovascular Research , Volume 46, Issue 1, April
2000, Pages 73–81,
- Juan Meng, Guohui Xiao, Juanjuan Zhang, Xing He, Min Ou, Jing Bi,
Rongqing Yang, Wencheng Di, Zhaoqin Wang, Zigang Li, Hong Gao, Lei Liu
& Guoliang Zhang (2020) Renin-angiotensin system inhibitors improve
the clinical outcomes of COVID-19 patients with hypertension, Emerging
Microbes &
Infections, 9:1, 757-760, DOI: 10.1080/22221751.2020.1746200